Are Patients with GBA-Parkinson Disease Good Candidates for Deep Brain Stimulation? A Longitudinal Multicentric Study on a Large Italian Cohort
Overview
Neurosurgery
Psychiatry
Authors
Affiliations
Background: variants increase the risk of developing Parkinson disease (PD) and influence its outcome. Deep brain stimulation (DBS) is a recognised therapeutic option for advanced PD. Data on DBS long-term outcome in carriers are scarce.
Objective: To elucidate the impact of variants on long-term DBS outcome in a large Italian cohort.
Methods: We retrospectively recruited a multicentric Italian DBS-PD cohort and assessed: (1) prevalence; (2) pre-DBS clinical features; and (3) outcomes of motor, cognitive and other non-motor features up to 5 years post-DBS.
Results: We included 365 patients with PD, of whom 73 (20%) carried variants. 5-year follow-up data were available for 173 PD, including 32 mutated subjects. GBA-PD had an earlier onset and were younger at DBS than non-GBA-PD. They also had shorter disease duration, higher occurrence of dyskinesias and orthostatic hypotension symptoms.At post-DBS, both groups showed marked motor improvement, a significant reduction of fluctuations, dyskinesias and impulsive-compulsive disorders (ICD) and low occurrence of most complications. Only cognitive scores worsened significantly faster in GBA-PD after 3 years. Overt dementia was diagnosed in 11% non-GBA-PD and 25% GBA-PD at 5-year follow-up.
Conclusions: Evaluation of long-term impact of variants in a large Italian DBS-PD cohort supported the role of DBS surgery as a valid therapeutic strategy in GBA-PD, with long-term benefit on motor performance and ICD. Despite the selective worsening of cognitive scores since 3 years post-DBS, the majority of GBA-PD had not developed dementia at 5-year follow-up.
Reese R, Koeglsperger T, Schrader C, Tonges L, Deuschl G, Kuhn A J Neurol. 2025; 272(3):219.
PMID: 39985674 PMC: 11846738. DOI: 10.1007/s00415-025-12915-6.
Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.
Vieira S, Mezabrovschi R, Toffoli M, Del Pozo S, Menozzi E, Mullin S Mov Disord. 2024; 39(12):2144-2154.
PMID: 39258449 PMC: 11657020. DOI: 10.1002/mds.30006.
Surgicogenomics: The Role of Genetics in Deep Brain Stimulation in Parkinson's Disease Patients.
Kalinderi K, Papaliagkas V, Fidani L Brain Sci. 2024; 14(8).
PMID: 39199492 PMC: 11352397. DOI: 10.3390/brainsci14080800.
Clinical neurophysiology in the treatment of movement disorders: IFCN handbook chapter.
Lefaucheur J, Moro E, Shirota Y, Ugawa Y, Grippe T, Chen R Clin Neurophysiol. 2024; 164:57-99.
PMID: 38852434 PMC: 11418354. DOI: 10.1016/j.clinph.2024.05.007.
Advanced therapies in Parkinson's disease: an individualized approach to their indication.
Schroter N, Sajonz B, Jost W, Rijntjes M, Coenen V, Groppa S J Neural Transm (Vienna). 2024; 131(11):1285-1293.
PMID: 38613674 PMC: 11502575. DOI: 10.1007/s00702-024-02773-3.